Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about IBO, unsubscribe in one click. Privacy
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Tenofovir | HIV | Early Phase 1 · NCT04898699 | Completed |
| Artemether-Lumefantrine Drug Combination | Malaria | Phase 4 · NCT05340153 | Unknown |
| Dihydroartemisinin-Piperaquine drug comb | Malaria | Phase 4 · NCT05340153 | Unknown |
| Fedratinib | Primary Myelofibrosis | Phase 3 · NCT03952039 | Completed |
| IMP4927 | Ovarian Cancer | Phase 3 · NCT04169997 | Active not recruiting |
| Senaparib (IMP4297) | Ovary Cancer | Phase 2 · NCT06617923 | Recruiting |
| ATR Inhibitor IMP9064 | Solid Tumor | Phase 2 · NCT05269316 | Recruiting |
| PARP1 Inhibitor IMP1734 | Advanced Solid Tumor | Phase 2 · NCT06253130 | Recruiting |
| PARP1 Inhibitor EIK1004 | Advanced Solid Tumors | Phase 2 · NCT06907043 | Recruiting |
| 14C-IMP4297 | Solid Tumor | Phase 1 · NCT05109832 | Completed |
| Potrasertib (IMP7068) | Advanced Solid Tumors | Phase 1 · NCT04768868 | Unknown |
Also used in these trials (approved or third-party drugs, not IBO's own candidates): Emtricitabine And Tenofovir Disoproxil Fumarate, Anti-Thymocyte Globulin (Rabbit), Temozolomide, Sirolimus, Mycophenolate Mofetil, Cyclophosphamide, Cyclosporine, Fluconazole.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
IBO holds $3,000 in cash and short-term investments and burns about $9,000/quarter from operations, an estimated runway of 1 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 0 · Low
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when IBO files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Vanguard Group Inc | Institution (13F) | 814,885 | 0.76% | 2025-12-31 |
| Blackrock Inc. | Institution (13F) | 259,946 | 0.24% | 2025-12-31 |
| Millennium Management Llc | Institution (13F) | 137,823 | 0.13% | 2025-12-31 |
| Geode Capital Management, LLC | Institution (13F) | 74,378 | 0.07% | 2025-12-31 |
| Two Sigma Investments, LP | Institution (13F) | 39,827 | 0.04% | 2025-12-31 |
| Two Sigma Securities, LLC | Institution (13F) | 22,695 | 0.02% | 2025-12-31 |
| Susquehanna International Group, LLP | Institution (13F) | 16,501 | 0.02% | 2025-12-31 |
| Jane Street Group, LLC | Institution (13F) | 14,086 | 0.01% | 2025-12-31 |
| HRT Financial LP | Institution (13F) | 13,533 | 0.01% | 2025-12-31 |
| State Street Corporation | Institution (13F) | 11,797 | 0.01% | 2025-12-31 |
Share count 107,821,231 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2025-12-31). Sources have different dates, so the split is approximate. Source: SEC EDGAR.
| Trade date | Insider | Transaction | Shares | Price | Owned after |
|---|---|---|---|---|---|
| 2026-09-24 filed 2026-09-24 |
DSS, INC. |
Sale (S) | 156 | $7.06 | 589,518 |
| 2026-09-23 filed 2026-09-24 |
DSS, INC. |
Sale (S) | 27 | $6.95 | 589,674 |
| 2026-09-22 filed 2026-09-24 |
DSS, INC. |
Sale (S) | 723 | $0.55 | 589,701 |
| 2026-03-27 filed 2026-03-30 |
Macko Todd D |
Sale (S) | 43,400 | $0.56 | 155,122 |
| 2026-03-25 filed 2026-03-30 |
Macko Todd D |
Sale (S) | 1,600 | $0.60 | 198,122 |
Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for IBO and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →